AZN
AstraZeneca PLC

18,757
Loading...
Loading...
News
all
press releases
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
Astrazeneca (AZN) closed at $85.31 in the latest trading session, marking a +1.98% move from the prior day.
Zacks·2d ago
News Placeholder
More News
News Placeholder
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
Zacks·2d ago
News Placeholder
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
Zacks·2d ago
News Placeholder
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·3d ago
News Placeholder
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Zacks·5d ago
News Placeholder
AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure
Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders.
Stocktwits·6d ago
News Placeholder
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Zacks·9d ago
News Placeholder
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.
Stocktwits·10d ago
News Placeholder
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
The latest trading day saw Astrazeneca (AZN) settling at $73.53, representing a -2.43% change from its previous close.
Zacks·10d ago
News Placeholder
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
Zacks·10d ago

Latest AZN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.